Core Viewpoint - SL BIO Ltd. is moving towards becoming a publicly traded company through a business combination with Horizon Space Acquisition II Corp., with the SEC declaring the registration statement effective on January 13, 2026 [1][2]. Company Overview - SL BIO Ltd. specializes in developing innovative cellular and gene therapies, focusing on regenerative medicine and cancer treatment. The company aims to utilize immune stem cells and bovine-derived milk exosomes for medical applications [4]. - The proprietary technologies of SL BIO include Armed-T and Gamma Delta T cells, as well as applications of exosomes in skincare and cancer recovery, positioning the company to potentially revolutionize the cell therapy and immuno-oncology sectors [4]. Business Combination Details - The business combination with HSPT is expected to result in the formation of SL Science Holding Limited, which will be listed on Nasdaq under the ticker symbol "SLBT" [2]. - An extraordinary general meeting of HSPT shareholders is scheduled for February 3, 2026, to approve the proposed transactions [2][3]. - The closing of the proposed transactions is contingent upon Nasdaq listing approvals, shareholder approval from HSPT, and the satisfaction of customary closing conditions [3].